Prelude Capital Management, LLC Viking Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $152,798 - $200,620	-23,328 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $249,873 - $346,304	-32,578 Reduced 58.27%	23,328 $194,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $188,529 - $247,227	24,872 Added 80.14%	55,906 $556,000
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $210,461 - $476,476	29,394 Added 1792.32%	31,034 $237,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $755,358 - $1.53 Million	-77,872 Reduced 97.94%	1,640 $29,000
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $308,506 - $1.01 Million	79,512 New	79,512 $755,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.